Sensus Healthcare Expands International Business to Meet Rising Patient Demand for Non-Invasive Skin Cancer and Keloid Treatments
BOCA RATON, Fla., April 19, 2018 /PRNewswire/ — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announced today that the Company is expanding its global business with SRT to meet growing demand for non-invasive, highly effective skin cancer and keloid treatments. Rick Golin, Executive Vice President of Oncology and International Sales, will lead this expansion. As part of this, he will facilitate recently signed new distribution agreements in International markets.
Read the full press release here.
The Benefits of SRT
Along with eliminating the risks for post-surgical infections and complications, the SRT-100™ provides patients and physicians with a safe and effective treatment option that offers many benefits, including:
- 95%+ cure rates that rival surgery
- No anesthesia, cutting, bleeding, stitching or pain
- No downtime or lifestyle restrictions
- Super cosmesis, no unsightly scarring
- No need for post-treatment reconstructive surgeries